SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids

References

• Bullard KM, Cowie CC, Lessem SE, et al. Prevalence of diagnosed diabetes in adults by diabetes type - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67:359–361.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, et al. Hypertension and diabetes mellitus: coprediction and time trajectories. Hypertension. 2018;71:422–428.
   PubMed Web of Science ®Google Scholar
• Khavandi M, Duarte F, Ginsberg HN, et al. Treatment of dyslipidemias to prevent cardiovascular disease in patients with type 2 diabetes. Curr Cardiol Rep. 2017;19:7.
   PubMed Web of Science ®Google Scholar
• Chamberlain JJ, Herman WH, Leal S, et al. Pharmacologic therapy for type 2 diabetes: synopsis of the 2017 American diabetes association standards of medical care in diabetes. Ann Intern Med. 2017;166:572–578.
   PubMed Web of Science ®Google Scholar
• Li J, Gong Y, Li C, et al. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis. Medicine (Baltimore). 2017;96:e7201.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Filippatos TD, Elisaf MS. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. Expert Opin Drug Metab Toxicol. 2017;13:399–408.
   PubMed Web of Science ®Google Scholar
• Ghezzi C, Wright EM. Regulation of the human Na+-dependent glucose cotransporter hSGLT2. Am J Physiol Cell Physiol. 2012;303:C348–54.
   PubMed Web of Science ®Google Scholar
• Filippatos T, Tsimihodimos V, Pappa E, et al. Pathophysiology of diabetic dyslipidaemia. Curr Vasc Pharmacol. 2017;15:566–575.
   PubMed Web of Science ®Google Scholar
• Verges B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58:886–899.
   PubMed Web of Science ®Google Scholar
• Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239:483–495.
   PubMed Web of Science ®Google Scholar
• Brown AM, Gibbons GF. Insulin inhibits the maturation phase of VLDL assembly via a phosphoinositide 3-kinase-mediated event. Arterioscler Thromb Vasc Biol. 2001;21:1656–1661.
   PubMed Web of Science ®Google Scholar
• Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2012;32:2104–2112.
   PubMed Web of Science ®Google Scholar
• Verges B. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis. 2010;211:353–360.
   PubMed Web of Science ®Google Scholar
• Ferre P, Foufelle F. SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm Res. 2007;68:72–82.
   PubMed Web of Science ®Google Scholar
• Taskinen MR, Adiels M, Westerbacka J, et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol. 2011;31:2144–2150.
   PubMed Web of Science ®Google Scholar
• Boren J, Watts GF, Adiels M, et al. Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity: multicenter tracer kinetic study. Arterioscler Thromb Vasc Biol. 2015;35:2218–2224.
   PubMed Web of Science ®Google Scholar
• Juntti-Berggren L, Berggren PO. Apolipoprotein CIII is a new player in diabetes. Curr Opin Lipidol. 2017;28:27–31.
   PubMed Web of Science ®Google Scholar
• Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol. 2017;13:731–739.
   PubMed Web of Science ®Google Scholar
• Abu-Farha M, Al-Khairi I, Cherian P, et al. Increased ANGPTL3, 4 and ANGPTL8/betatrophin expression levels in obesity and T2D. Lipids Health Dis. 2016;15:181.
   PubMed Web of Science ®Google Scholar
• Lagos KG, Filippatos TD, Tsimihodimos V, et al. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids. 2009;44:9–16.
   PubMed Web of Science ®Google Scholar
• Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab. 2005;31:429–439.
   PubMed Web of Science ®Google Scholar
• Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am. 2006;35:491–510, vii-viii.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Rizos EC, Tsimihodimos V, et al. Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A(2) in subjects with prediabetes. Lipids. 2013;48:547–555.
   PubMed Web of Science ®Google Scholar
• Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 2012;51:314–324.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, et al. High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? Curr Med Chem. 2014;21:2917–2926.
   PubMed Web of Science ®Google Scholar
• Wang J, Stancakova A, Soininen P, et al. Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men. J Intern Med. 2012;272:562–572.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453–462.
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9:533–571.
   PubMed Web of Science ®Google Scholar
• Gazi IF, Tsimihodimos V, Tselepis AD, et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther. 2007;7:53–72.
   PubMed Web of Science ®Google Scholar
• Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005;51:2264–2273.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K, Koulouris S, et al. Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes? Int J Clin Pract. 2010;64:1632–1642.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes. 2007;115:477–482.
   PubMed Web of Science ®Google Scholar
• Stahel P, Xiao C, Hegele RA, et al. The atherogenic dyslipidemia complex and novel approaches to cardiovascular disease prevention in diabetes. Can J Cardiol. 2018;34(5):595-604.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Florentin M, Georgoula M, et al. Pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2017;10:187–200.
   PubMed Web of Science ®Google Scholar
• Dunn FL. Management of dyslipidemia in people with type 2 diabetes mellitus. Rev Endocr Metab Disord. 2010;11:41–51.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2:370–380.
   PubMed Web of Science ®Google Scholar
• Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984–993.
   PubMed Web of Science ®Google Scholar
• Bode B, Stenlof K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17:294–303.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Goda M, Yokota S, et al. Effects of baseline blood pressure and low-density lipoprotein cholesterol on safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv Ther. 2015;32:1085–1103.
   PubMed Web of Science ®Google Scholar
• Bays HE, Sartipy P, Xu J, et al. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. J Clin Lipidol. 2017;11:450–8.e1.
   PubMed Web of Science ®Google Scholar
• Cha SA, Park YM, Yun JS, et al. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis. 2017;16:58.
   PubMed Web of Science ®Google Scholar
• Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS One. 2016;11:e0166125.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Zhu QQ, Chen YH, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. 2018;7(2):e007165.
   Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44:375–393.
   PubMed Web of Science ®Google Scholar
• Li J, Shao YH, Wang XG, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis. Endocr J. 2018;65:335–344.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Fukui T, Nakanishi N, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16:8.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Bonora BM, Zatti G, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017;16:42.
   PubMed Web of Science ®Google Scholar
• Bando Y, Tohyama H, Aoki K, et al. Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus. J Clin Transl Endocrinol. 2016;6:1–7.
   PubMedGoogle Scholar
• Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65:2032–2038.
   PubMed Web of Science ®Google Scholar
• Daniele G, Xiong J, Solis-Herrera C, et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care. 2016;39:2036–2041.
   PubMed Web of Science ®Google Scholar
• Kern M, Kloting N, Mark M, et al. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism. 2016;65:114–123.
   PubMed Web of Science ®Google Scholar
• Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–514.
   PubMed Web of Science ®Google Scholar
• Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves beta-cell function. J Clin Endocrinol Metab. 2015;100:1927–1932.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Filippatos TD, Elisaf MS. SGLT2 inhibitors and the kidney: effects and mechanisms. Diabetes Metab Syndr. 2018;12:1117–1123.
   Web of Science ®Google Scholar
• Cavaiola TS, Pettus J. Cardiovascular effects of sodium glucose cotransporter 2 inhibitors. Diabetes Metab Syndr Obes. 2018;11:133–148.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Filippatos TD, Filippas-Ntekouan S, et al. Renoprotective effects of SGLT2 inhibitors: beyond glucose reabsorption inhibition. Curr Vasc Pharmacol. 2017;15:96–102.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opin Pharmacother. 2016;17:1581–1583.
   PubMed Web of Science ®Google Scholar
• Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgrad Med. 2018;130:72–82.
   PubMed Web of Science ®Google Scholar
• Danne T, Biester T, Kordonouri O. Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care. Diabetes Technol Ther. 2018;20:S269–S77.
   PubMed Web of Science ®Google Scholar
• Spatola L, Finazzi S, Angelini C, et al. SGLT1 and SGLT1 inhibitors: A role to be assessed in the current clinical practice. Diabetes Ther. 2018;9:427–430.
   PubMed Web of Science ®Google Scholar